Status of work in June
AOTMiT begins work on the Ministry of Health’s orders in May:
- Keytruda (pembrolizumab) in the treatment of patients with urothelial cancer
- Tagrisso (osimertinib) in the treatment of patients with lung cancer and pleural mesothelioma
- Phesgo (pertuzumab, trastuzumab) in the treatment of breast cancer patients
- Tecartus (brexucabtagene autoleucel) in the treatment of patients with B-cell lymphomas
- Padcev (enfortumab vedotin) in the treatment of patients with urothelial cancer
The listed orders are available on the AOTMiT Public Information Bulletin.